Diagnosis and treatment of oropharyngeal candidiasis

Oral and Maxillofacial Surgery Clinics of North America

Volumn 15, Issue 1, 2003, Pages 91-102

  Epstein, Joel B ^a,b  

^a Chicago Cancer Center   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANILINE DERIVATIVE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BENZIMIDAZOLE; CHLORHEXIDINE GLUCONATE; CLOTRIMAZOLE; CRYSTAL VIOLET; FLUCONAZOLE; HEMOPOIETIC GROWTH FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIDAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LISTERINE; MICONAZOLE; NATAMYCIN; NYSTATIN; OMEPRAZOLE; PHENYTOIN; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; RIFAMPICIN; STEROID; TOOTHPASTE; TRIAZOLE; UNINDEXED DRUG;

ANTIBIOTIC SENSITIVITY; BLOOD TOXICITY; CANDIDA ALBICANS; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CARDIOTOXICITY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BINDING; FUNGUS ISOLATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER TOXICITY; LUNG TOXICITY; MORBIDITY; MORTALITY; MOUTH FLORA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; REVIEW; RISK FACTOR; THRUSH;

EID: 0037309234     PISSN: 10423699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1042-3699(02)00071-7     Document Type: Review

References (89)

1. Epstein JB. Antifungal therapy in oropharyngeal mycotic infections. Oral Surg Oral Med Oral Pathol 1990;69:32-41.
2. Guida RA. Candidiasis of the oropharynx and esophagus. Ear Nose Throat J 1988;67:832-40.
3. Dreizen S. Oral candidiasis. Am J Med 1984;30:28-33.
4. Budtz-Jörgensen E. Etiology, pathogenesis therapy and prophylaxis of oral yeast infections. Acta Odontol Scand 1990;48:61-9.
5. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol 1994; 31(Suppl):51-5.
6. Meyer RD, Holmberg K. Fungal infection in HIV-infected patients. In: Homberg K, Meyer R, editors. Diagnosis and therapy of systemic fungal infections. New York: Raven Press; 1989. p. 79-100.
7. Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology 2001;15:351-69.
8. de Pauw BE. Advances in the management of invasive fungal infections in organ transplant recipients: step by step. Transpl Infect Dis 2000;2:48-50.
9. Donnelly JP. A strategy for managing fungal infections in haematopoietic stem cell transplantation. Transplant Infect Dis 2000;3:88-95.
10. Wingard JR. Approach to invasive fungal infection after blood or marrow transplantation. Transplant Proc 2000;32:1543-4.
11. Santelmann H, Laerum E, Roennevig J, Fagertun HE. Effectiveness of nystatin in polysymptomatic patients: a randomized, double-blind trial with nystatin versus placebo in general practice. Fam Pract 2001;18:258-65.
12. Peterson DE. Oral candidiasis. Clin Geriatr Med 1992; 8:513-27.
13. Dhondt F, Ninane J, De Benle K, et al. Oral candidosis: treatment with absorbable and non-absorbable antifungal agents in children. Mycoses 1992;35:1-8.
14. Francis P, Walsh TJ. Current approaches to the management of fungal infections in cancer patients. Oncology 1992;6:81-92.
15. Prentice AG. Oral and gastrointestinal candidosis: prophylaxis during immunosuppressive therapy. Mycoses 1989;32(Suppl 2):42-6.
16. DeGregorio MW, Lee WMF, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982;50: 2780-4.
17. Stevens DA, Green SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Arch Intern Med 1991;151: 2458-64.
18. Epstein JB, Ransier A, Lunn R, Chin E, Jacobson J, Le N, et al. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:291-6.
19. Epstein JB, Vickars L, Spinelli J, Reece D. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1991; 73:682-9.
20. Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993;76: 169-74.
21. Bergmann OJ. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloleukemia. Scand J Infect Dis 1991;2:355-66.
22. Bergmann OJ, Andersen PL. Acute oral candidiasis during febrile episodes in immunocompromised patients with haematologic malignancies. Scand J Infect Dis 1990;22:353-8.
23. Rodu B, Carpenter JT, Jones MR. The pathogenesis and clinical significance of cytologically detectable oral Candida in acute leukemia. Cancer 1988;62:2042-6.
24. Dupont B, Graybiull JR, Armstrong D, et al. Fungal infections in AIDS patients. Journal of Medical and Veterinary Mycology 1992;30(Suppl 1):19-28.
25. Koks CHW, Schepens MHJ, Burger DM, et al. Drug development report (9): fluconazole in the treatment and prophylaxis of oral candidosis in HIV-infected patients. J Drug Dev Clin Pract 1993;5:235-49.
26. Heinic GS, Stevens DA, Greenspan D. Fluconazole-resistant Candida in AIDS patients. Oral Surg Oral Med Oral Pathol 1993;76:711-5.
27. Pollock JJ, Santarpia III RP , Heller HM, et al. Determination of salivary anticandidal activities in healthy adults and patients with AIDS: a pilot study. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5:610-8.
28. Conant MA. The AIDS epidemic. J Am Acad Dermatol 1994;31:847-50.
29. Jewell ME, Sweet DE. Oral and dermatologic manifestations of HIV infection. Postgrad Med 1994;96: 105-16.
30. Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practices of infectious diseases. New York: Churchill-Livingstone; 1995. p. 2289-301.
31. Epstein JB, Komiyama K, Duncan D. Oral topical steroids and secondary oral candidiasis. J Oral Med 1986; 41:223-7.
32. Crislip MA, Edwards JE. Candidiasis. Infect Dis Clin North Am 1989;3:103-33.
33. Lewis MAO, Samaranyake LP, Lamey PJ. Diagnosis and treatment of oral candidiasis. J Oral Maxillofac Surg 1991;49:996-1002.
34. Bissell V, Felix DH, Wray D. Comparative trial of fluconazole and amphotericin in the treatment of denture stomatitis. Oral Surg Oral Med Oral Pathol 1993; 76:35-9.
35. Berkow R. The Merck manual of diagnosis and therapy. 16th edition. Rahway (NJ): Merck & Co.; 1992.
36. Epstein JB, Truelove EL, Izutzu KT. Oral candidiasis: pathogenesis and host defense. Rev Infect Dis 1984; 6:96-106.
37. Epstein JB, Pearshall NN, Truelove EL. Quantitative relationships between Candida albicans in saliva and the clinical status of human subjects. J Clin Microbiol 1980;12:475-6.
38. Rex JH, Cooper CR, Merz WG, et al. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995;39: 906-9.
39. Barchiesi F, Del Poeta M, Morbiducci V, et al. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal against Candida spp and Cryptococcus neoformans. Mycopathologia 1993; 124:19-25.
40. Woods GL, Washington JA. The clinical and the microbiology laboratory. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practices of infectious diseases. New York: Churchill-Livingstone; 1995. p. 169-99.
41. Galgiani JN. Antifungal susceptibility tests. Antimicrob Agents Chemother 1987;31:1867-70.
42. Galls HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
43. Korting HC, Ollert M, Georgii A, Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1988;26:2626-31.
44. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30: 677-98.
45. Judd G. Oral candidiasis: treatment choices. Continuing Education 1989;16:21-2.
46. Datry A. Candidose digestive et infection vih: actualites cliniques et therapeutiaques. Mycology Medicine 1992;2(Suppl I):5-14.
47. Samaranayake LP, Ferguson MM. Delivery of antifungal agents to the oral cavity. Adv Drug Deliv Rev 1994;13:161-79.
48. Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. Journal of Medical and Veterinary Mycology 1994;32:389-93.
49. Meiller TF, Kelley JI, Jabra-Rizk MA, DePaola LG, Baqui A, Falkler WA. In vitro studies of the efficacy of antimicrobials against fungi. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:663-70.
50. Bennett JE. Antimicrobial agents, antifungal agents. In: Gilman AG, Rall TM, Nies AS, editors. The pharmacological basis of therapeutics. 8th edition. New York: Pergamon Press; 1990. p. 1165-81.
51. Barkvoll P, Atramadal A. Effect on nystatin and chlorhexidine digluconate on Candida albicans. Oral Surg Oral Med Oral Pathol 1989;67:279-81.
52. Barkvoll P, Hurlen B. Conventional treatment or oral candidiasis: new aspects. Nor Tannlaegeforen Tid 1989;99:116-9.
53. Philpott-Howard JN, Wade JJ, Mufti GJ, et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-84.
54. Egger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: a prospective, randomized, single-center study. Support Care Cancer 1995;3:139-46.
55. Donnelly JP, Starke ID, Galton DAG, et al. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukemia. J Hosp Infect 1984;5:83-91.
56. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-8.
57. Owens NJ, Nightingale CH, Schweizer RT, et al. Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 1984;144:290-3.
58. Shechtman LB, Funaro L, Robin T, et al. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am J Med 1984;76:91-4.
59. Goldstein SM. Advances in the treatment of superficial Candida infections. Semin Dermatol 1993;12:315-30.
60. Uchida K, Yamaguchi H. Susceptibility to miconazole (base) of isolates from the oral cavity and esophagus of patients with mycosis. Jpn J Antibiot 1991;44:109-16.
61. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
62. Gupta KL, Ghosh AK, Kochhar R, et al. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols. Am J Gastroenterol 1994;89:1062-5.
63. van der Bijl P, Arendorf TM. Itraconazole and fluconazole in oropharyngeal candidiasis. Ann Dent 1993; 52:12-6.
64. Meunier F. Fluconazole treatment of fungal infections in the immunocompromised host. Semin Oncol 1990; 17(Suppl 6):19-23.
65. Hansen RM, Reinerio N, Sohnle PG, et al. Ketoconazole in the prevention of candidiasis in patients with cancer: a prospective, randomized, controlled, double-blind study. Arch Intern Med 1987;147:710-2.
66. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
67. Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990;12(Suppl 3): 334-7.
68. Conly A, Renin R, Johnson J, et al. Disseminated candidosis due to amphoteric B resistant Candida albicans. J Infect Dis 1992;165:761-4.
69. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
70. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19:687-92.
71. Ng TTC, Denning DW. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J Infect 1993;26:117-25.
72. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994; 19:684-6.
73. Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 1994;8:945-50.
74. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989;18:554-64.
75. Manso E, Montillo M, Discepoli G, Leoni P. Fluconazole resistance of Candida krusei. Boli Ist Sieroter Milan 1991;70:527-9.
76. Redding S, Smith J, Farinacci G. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
77. Laguna F, Rodriguez-Tudela JL, Enriquez A. Fungemia due to fluconazole-resistant Candida albicans in a patient with AIDS. Clin Infect Dis 1994;19:542-3.
78. Lucatorto FM, Franker C, Hardy WD, Chafey S. Treatment of refractory oral candidiasis with fluconazole: a case report. Oral Surg Oral Med Oral Pathol 1991; 71:42-4.
79. Fan-Havard P, Capano D, Smith SM, et al. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1991;35:2302-5.
80. Akova M, Akalin HE, Uzun O, Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991;10:598-9.
81. de Vries-Hospers HG, Mulder NH, Sleijfer DT, van Saene HK. The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 1982;10:71-5.
82. de Vries-Hospers HG, van der Waaij D. Salivary concentrations of amphotericin B following its use as an oral lozenge. Infection 1980;8:63-5.
83. Terrell CL, Hermans PE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1987;62:1116-28.
84. Ghosh A, Ghosh JJ. Effect of nystatin and amphotericin B on the growth of Candida albicans. Ann Biochem Exp Med 1963;23:29-44.
85. Lechevalier H. Comparison of the in vitro activity of four polyenic antifungal antibiotics. Antibiotic Annual 1959;614-8.
86. Alban J, Groel JT. Amphotericin B oral suspension in the treatment of thrush. Curr Ther Res 1970;12:479-84.
87. Brandell R, Chase SL, Cohn JR. Treatment of oral candidiasis with amphotericin B solution. Clin Pharm 1988;7:70-2.
88. Stough AR, Groel JT, Kroeger WH. Amphotericin B, a new antifungal agent for the prophylaxis of antibiotic-induced moniliasis. Antibiot Med Clin Ther 1959; 6:653-61.
89. Stevens DA, Kullberg BJ, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Medical Mycology 2000;3:305-15.